Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment

American Journal of Clinical Oncology
Maurizia Dalla PalmaMaria O Nicoletto

Abstract

This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m(2), respectively, over 2 day, every 4 weeks. Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Markman, W Hoskins
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D I JodrellE Wiltshaw
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·J M ExtraM Marty
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A JakobsenI Stroeyer
Dec 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P CholletE Cvitkovic
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P SouliéE Cvitkovic
Mar 13, 1999·Seminars in Oncology Nursing·K G O'Connor
Apr 29, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A du BoisJ T Thigpen
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S GiacchettiF Lévi
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P NeijtH C van Houwelingen
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M A BookmanR F Ozols
Nov 18, 2004·Journal of the National Cancer Institute·Paul A VaseyUNKNOWN Scottish Gynaecological Cancer Trials Group
Oct 22, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A du BoisUNKNOWN Organizational team of the two prior International OCCC
Mar 12, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Roger von MoosAxel Hauschild
Oct 13, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Maria Ornella NicolettoMartin E Donach

❮ Previous
Next ❯

Citations

Jul 1, 2015·Expert Opinion on Investigational Drugs·Stefano BoglioloArsenio Spinillo
Jul 28, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Shao-Fei YuanJian-Ping Xiong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.